<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for treating oral leukoplakia to prevent oral cancer - Lodi, G - 2016 | Cochrane Library</title> <meta content="Interventions for treating oral leukoplakia to prevent oral cancer - Lodi, G - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001829.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for treating oral leukoplakia to prevent oral cancer - Lodi, G - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001829.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001829.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for treating oral leukoplakia to prevent oral cancer" name="citation_title"/> <meta content="Giovanni Lodi" name="citation_author"/> <meta content="Università degli Studi di Milano" name="citation_author_institution"/> <meta content="giovanni.lodi@unimi.it" name="citation_author_email"/> <meta content="Roberto Franchini" name="citation_author"/> <meta content="Università degli Studi di Milano" name="citation_author_institution"/> <meta content="Saman Warnakulasuriya" name="citation_author"/> <meta content="King's College London" name="citation_author_institution"/> <meta content="Elena Maria Varoni" name="citation_author"/> <meta content="Università degli Studi di Milano" name="citation_author_institution"/> <meta content="Andrea Sardella" name="citation_author"/> <meta content="Università degli Studi di Milano" name="citation_author_institution"/> <meta content="Alexander R Kerr" name="citation_author"/> <meta content="New York University College of Dentistry" name="citation_author_institution"/> <meta content="Antonio Carrassi" name="citation_author"/> <meta content="Università degli Studi di Milano" name="citation_author_institution"/> <meta content="L CI MacDonald" name="citation_author"/> <meta content="School of Dentistry, The University of Manchester" name="citation_author_institution"/> <meta content="Helen V Worthington" name="citation_author"/> <meta content="School of Dentistry, The University of Manchester" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD001829.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/07/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001829.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001829.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001829.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Leukoplakia, Oral [*therapy]; Mouth Neoplasms [*prevention &amp; control]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001829.pub4&amp;doi=10.1002/14651858.CD001829.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="l7AWCCEw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001829\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001829\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","ru","ms","ja","hr","fa","th"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001829.pub4",title:"Interventions for treating oral leukoplakia to prevent oral cancer",firstPublishedDate:"Jul 29, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Oral Health Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001829.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001829.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001829.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001829.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001829.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001829.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001829.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001829.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001829.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001829.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9131 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001829.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-sec-0117"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-sec-0113"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/appendices#CD001829-sec-0122"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/table_n/CD001829StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/table_n/CD001829StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for treating oral leukoplakia to prevent oral cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Giovanni Lodi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0003">Roberto Franchini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0004">Saman Warnakulasuriya</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0005">Elena Maria Varoni</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0006">Andrea Sardella</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0007">Alexander R Kerr</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0008">Antonio Carrassi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0009">L CI MacDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information#CD001829-cr-0010">Helen V Worthington</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information/en#CD001829-sec-0135">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 July 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001829.pub4">https://doi.org/10.1002/14651858.CD001829.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001829-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001829-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001829-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001829-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/th#CD001829-abs-0014">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001829-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001829-abs-0001" lang="en"> <section id="CD001829-sec-0001"> <h3 class="title" id="CD001829-sec-0001">Background</h3> <p>Oral leukoplakia is a relatively common oral lesion that, in a small proportion of people, precedes the development of oral cancer. Most leukoplakias are asymptomatic; therefore, the primary objective of treatment should be to prevent onset of cancer. This review updates our previous review, published in 2006. </p> </section> <section id="CD001829-sec-0002"> <h3 class="title" id="CD001829-sec-0002">Objectives</h3> <p>To assess the effectiveness, safety and acceptability of treatments for leukoplakia in preventing oral cancer. </p> </section> <section id="CD001829-sec-0003"> <h3 class="title" id="CD001829-sec-0003">Search methods</h3> <p>We searched the following electronic databases: Cochrane Oral Health's Trials Register (to 16 May 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>the Cochrane Library</i>, 2016, Issue 4), MEDLINE Ovid (1946 to 16 May 2016), Embase Ovid (1980 to 16 May 2016) and CancerLit via PubMed (1950 to 16 May 2016). We searched the metaRegister of Controlled Trials (to 10 February 2015), ClinicalTrials.gov (to 16 May 2016) and the World Health Organization (WHO) International Clinical Trials Registry Platform for ongoing trials (to 16 May 2016). We placed no restrictions on the language or date of publication when searching electronic databases. </p> </section> <section id="CD001829-sec-0004"> <h3 class="title" id="CD001829-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) that enrolled people with a diagnosis of oral leukoplakia and compared any treatment versus placebo or no treatment. </p> </section> <section id="CD001829-sec-0005"> <h3 class="title" id="CD001829-sec-0005">Data collection and analysis</h3> <p>We collected data using a data extraction form. Oral cancer development, demonstrated by histopathological examination, was our primary outcome. Secondary outcomes were clinical resolution of the lesion, improvement of histological features and adverse events. We contacted trial authors for further details when information was unclear. When valid and relevant data were available, we conducted a meta‐analysis of the data using a fixed‐effect model when we identified fewer than four studies with no heterogeneity. For dichotomous outcomes, we calculated risk ratios (RRs) and 95% confidence intervals (CIs). We assessed risk of bias in studies by using the Cochrane tool. We assessed the overall quality of the evidence by using standardised criteria (Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE)). </p> </section> <section id="CD001829-sec-0006"> <h3 class="title" id="CD001829-sec-0006">Main results</h3> <p>We included 14 studies (909 participants) in this review. Surgical interventions, including laser therapy and cryotherapy, have never been studied by means of an RCT that included a no treatment or placebo arm. The included trials tested a range of medical and complementary treatments, in particular, vitamin A and retinoids (four studies); beta carotene or carotenoids (three studies); non‐steroidal anti‐inflammatory drugs (NSAIDs), specifically ketorolac and celecoxib (two studies); herbal extracts (four studies), including tea components, a Chinese herbal mixture and freeze‐dried black raspberry gel; bleomycin (one study); and Bowman‐Birk inhibitor (one study). </p> <p>We judged one study to be at low risk of bias, seven at unclear risk and six at high risk. In general, we judged the overall quality of the evidence to be low or very low, so findings are uncertain and further research is needed. </p> <p>Five studies recorded cancer incidence, only three of which provided useable data. None of the studies provided evidence that active treatment reduced the risk of oral cancer more than placebo: systemic vitamin A (RR 0.11, 95% CI 0.01 to 2.05; 85 participants, one study); systemic beta carotene (RR 0.71, 95% CI 0.24 to 2.09; 132 participants, two studies); and topical bleomycin (RR 3.00, 95% CI 0.32 to 27.83; 20 participants, one study). Follow‐up ranged between two and seven years. </p> <p>Some individual studies suggested effectiveness of some proposed treatments, namely, systemic vitamin A, beta carotene and lycopene, for achieving clinical resolution of lesions more often than placebo. Similarly, single studies found that systemic retinoic acid and lycopene may provide some benefit in terms of improvement in histological features. Some studies also reported a high rate of relapse. </p> <p>Side effects of varying severity were often described; however, it seems likely that interventions were well accepted by participants because drop‐out rates were similar between treatment and control groups. </p> </section> <section id="CD001829-sec-0007"> <h3 class="title" id="CD001829-sec-0007">Authors' conclusions</h3> <p>Surgical treatment for oral leukoplakia has not been assessed in an RCT that included a no treatment or placebo comparison. Nor has cessation of risk factors such as smoking been assessed. The available evidence on medical and complementary interventions for treating people with leukoplakia is very limited. We do not currently have evidence of a treatment that is effective for preventing the development of oral cancer. Treatments such as vitamin A and beta carotene may be effective in healing oral lesions, but relapses and adverse effects are common. Larger trials of longer duration are required to properly evaluate the effects of leukoplakia treatments on the risk of developing oral cancer. High‐quality research is particularly needed to assess surgical treatment and to assess the effects of risk factor cessation in people with leukoplakia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001829-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001829-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD001829-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD001829-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001829-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001829-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD001829-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001829-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001829-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD001829-abs-0015">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001829-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001829-abs-0004" lang="en"> <h3>Interventions for treating oral leukoplakia to prevent oral cancer</h3> <p><b>Review question</b> </p> <p>People with oral leukoplakia are at higher risk of developing oral cancer than those with normal oral mucosa. This review, produced through <a href="http://oralhealth.cochrane.org/" target="_blank">Cochrane Oral Health</a>, seeks to evaluate whether people affected by leukoplakia can benefit from surgical, medical or complementary treatments, either local or systemic. In particular, we conducted this review to find out which, if any, treatment is able to prevent people with leukoplakia of the mouth from getting oral cancer. This review updates our previous review published in 2006. </p> <p><b>Background</b> </p> <p>Oral leukoplakia is a white patch formed in the mouth lining that cannot be rubbed off. It often does not hurt and may go unnoticed for years. People with leukoplakia develop oral cancer more often than people without it. Preventing this is critical because rates of oral cancer survival longer than five years after diagnosis are low. Drugs, surgery and other therapies have been tried for treatment of oral leukoplakia. </p> <p><b>Objectives</b> </p> <p>This review aimed to evaluate whether treatments for oral leukoplakia are effective in preventing oral cancer, and safe and acceptable to patients. </p> <p><b>Study characteristics</b> </p> <p>The evidence on which this review is based is up‐to‐date as of May 2016. We found 14 randomised controlled trials (RCTs) of medical and complementary treatments, which involved 909 participants in total. Treatments included herbal extracts, anti‐inflammatory drugs, vitamin A, beta carotene supplements and others. Surgical treatment has not been compared with placebo or no treatment in an RCT. </p> <p><b>Key results</b> </p> <p>Cancer development was measured in studies of three treatments: systemic vitamin A, systemic beta carotene and topical bleomycin. None of these treatments showed effectiveness in preventing cancer development, as measured up to two years for vitamin A and beta carotene, and seven years for bleomycin. </p> <p>Some individual studies of vitamin A and beta carotene suggested that these treatments may be effective for improving or healing oral lesions. However, some studies observed a high rate of relapse in participants whose lesions were initially resolved by treatment. </p> <p>Most treatments caused side effects of differing severity in a high proportion of participants. </p> <p>It seems likely that interventions were well accepted by participants because drop‐out rates were similar between treatment and control groups. </p> <p><b>Quality of the evidence</b> </p> <p>The available evidence is very limited. Most interventions were assessed by only one small study. Most studies had problems in the way they were conducted, making their results unreliable. We judged the quality of evidence for the outcome of cancer development to be very low. </p> <p><b>Author conclusions</b> </p> <p>Larger, better studies of longer duration are required. As well as further studies of drug treatment and alternative treatments like vitamins, studies are needed to evaluate the effectiveness and safety of surgery, and of stopping risk factor habits such as smoking. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001829-sec-0117" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001829-sec-0117"></div> <h3 class="title" id="CD001829-sec-0118">Implications for practice</h3> <section id="CD001829-sec-0118"> <p>No randomised controlled trials (RCTs) on surgical treatment for people who have oral leukoplakia have included placebo and active treatment arms. Nor have RCTs examined risk factor cessation (e.g. smoking). Therefore, the effectiveness of these interventions cannot be reliably assessed. None of the medical and complementary treatments studied (vitamin A, beta carotene, bleomycin) has been shown to be effective in preventing cancer onset in people with leukoplakia, and, despite the findings of some studies that vitamin A or beta carotene may be effective in reducing or even resolving oral leukoplakia in the short term, the risk of subsequent relapse seems high. </p> </section> <h3 class="title" id="CD001829-sec-0119">Implications for research</h3> <section id="CD001829-sec-0119"> <p>Although surgery remains the treatment option favoured by most clinicians, the effectiveness of surgery compared with no treatment ("wait and see") has not been assessed in RCTs for prevention of cancer development in people with leukoplakia. Research is needed to assess surgical treatment of patients with leukoplakia and to evaluate effects of risk factor cessation in people with leukoplakia. Larger, better conducted trials of longer duration are required to properly evaluate the effects of any treatment on malignant transformation rates, which should be considered the primary outcome when effectiveness of treatments for leukoplakia is tested. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001829-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001829-sec-0029"></div> <div class="table" id="CD001829-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vitamin A or retinoids versus placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Systemic or topical vitamin A vs placebo for treating leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with oral leukoplakia<br/> <b>Intervention:</b> vitamin A or retinoids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin A or retinoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer development at 24 months from start of treatment (treatment lasted 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (1 to 191) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.11<br/> (0.01 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study evaluated systemic treatment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical resolution (not completely resolved) at 4 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Studies could not be combined in meta‐analysis</p> <p>One study evaluated topical treatment and did not find evidence of benefit</p> <p>3 studies of systemic vitamin A ‐ 2 showed benefit in terms of clinical resolution, and 1 did not </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved) at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>889 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1000 (213 to 676)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.43 (0.24 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study evaluated systemic treatment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention at 4 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>3 studies (1 each evaluating topical acitretin, topical 13‐cis‐retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13‐cis‐retinoic acid (1 to 2 mg/kg/d) caused adverse effects of varying severity in 79% of participants </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus; d = day </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>From event rate in control group<br/> <sup>a</sup>Downgraded 3 levels as single small study at unclear risk of bias with very imprecise result<br/> <sup>b</sup>Downgraded as single small study </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001829-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with oral leukoplakia<br/> <b>Intervention:</b> systemic beta carotene<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with beta carotene or carotenoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer development at</p> <p>24 months from start of treatment (treatment lasted 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/> (26 to 238) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/> (0.24 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical resolution (not completely resolved) at</p> <p>5 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>The 3 studies could not be combined in meta‐analysis. 2 found benefit for systemic beta carotene, and 1 did not </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved)</p> <p>at 5 months (treatment lasted 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> <p>(100 to 383)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.24 (0.12 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention at 5 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Systemic beta carotene did not cause any adverse effects in 1 study supplementing 10 mg/d, and caused adverse effects of varying severity in 9% of participants in another study supplementing 360 mg/wk </p> <p>No adverse effects were reported by participants treated with systemic lycopene in one study </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus; d = day; wk = week </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> From event rate in control group<br/> <sup>a</sup>Downgraded 3 levels for unclear or high risk of bias and serious imprecision<br/> <sup>b</sup>Downgraded 2 levels as single small study at unclear risk of bias </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001829-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Non‐steroidal anti‐inflammatory drugs (NSAIDs) vs placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NSAIDs vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral leukoplakia </p> <p><b>Intervention:</b> NSAIDs </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer development</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical resolution (not completely resolved) at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>1 study evaluated systemic treatment and 1 evaluated topical treatment. Neither found benefit for NSAIDs </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety of the intervention</p> <p>over 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Systemic celecoxib (1 study) ‐ 32 intervention participants reported 56 adverse effects and 20 placebo participants in the placebo group reported 20 adverse effects. Minor adverse events included dizziness, diarrheoa and abdominal pain. 4 participants (2 from the placebo group and 2 from an intervention group) had grade 3 adverse events. 2 participants permanently discontinued treatment owing to an adverse event (grade 2 vision abnormality and hypertension in a participant receiving 400 mg twice daily of celecoxib and a grade 3 ischaemic cerebrovascular accident in a participant receiving 200 mg twice daily of celecoxib) </p> <p>Ketorolac oral rinse (1 study) caused adverse effects of varying severity in 29% of participants </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD001829-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Herbal extracts vs placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Herbal extracts vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral leukoplakia </p> <p><b>Intervention:</b> herbal extracts ‐ tea components; a Chinese herbal mixture; curcumin chewing gum; freeze‐dried black raspberry gel </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with herbal extracts</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer development</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical resolution (not completely resolved) at 3 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>3 studies (1 of freeze‐dried black raspberry gel, 1 of green tea extract capsules and 1 of mixed tea treatment) did not find evidence of benefit for the intervention </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved) at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>2 studies (1 of green tea extract capsules and 1 of freeze‐dried raspberry gel) did not find evidence of benefit from these interventions </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention up to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>3 studies measured adverse effects: green tea extract capsules caused high frequency (93%) of adverse effects of varying severity in 1 study; the mixed tea treatment study did not mention adverse effects; freeze‐dried black raspberry gel did not cause any adverse effects </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD001829-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Topical bleomycin vs placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topical bleomycin vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with oral leukoplakia<br/> <b>Intervention:</b> topical bleomycin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical bleomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer development up to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> <p>(27 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00<br/> (0.32 to 27.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical resolution (not completely resolved)</p> <p>at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>917 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>504 per 1000 (266 to 954)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.55 (0.29 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved) at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>818 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401 per 1000 (180 to 900)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.49 (0.22 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention up to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>"All patients in the bleomycin group developed erythema with erosion by the end of the applications, whereas erythema developed in the placebo group. Discomfort was reported by 60% of the bleomycin group, but analgesics were not required. Taste of the topical application as well‐tolerated. There was no observed systemic toxicity in the patient groups" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> From event rate in control group<br/> <sup>a</sup>Downgraded 3 levels as a single small study at unclear risk of bias with imprecise result </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001829-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bowman‐Birk inhibitor versus placebo for oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bowman‐Birk inhibitor vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral leukoplakia </p> <p><b>Intervention:</b> Bowman‐Birk inhibitor </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Bowman‐Birk inhibitor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer development</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical resolution (not completely resolved) at 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>957 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>957 per 1000</p> <p>(871 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (0.91 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved) at 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention up to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Trial authors reported that there were no significant adverse effects. 33 participants in the intervention group reported 75 adverse effects. 25 participants in the placebo group reported 63 adverse effects </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> From event rate in control group<br/> <sup>a</sup>Downgraded 2 levels as a single small study at high risk of bias </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001829-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001829-sec-0030"></div> <section id="CD001829-sec-0031"> <h3 class="title" id="CD001829-sec-0031">Description of the condition</h3> <p>"The term leukoplakia should be used to recognize white plaques of questionable risk having excluded (other) known diseases or disorders that carry no increased risk for cancer" (<a href="./references#CD001829-bbs2-0074" title="WarnakulasuriyaS , JohnsonNW , Van derWaalI . Nomenclature and classification of potentially malignant disorders of the oral mucosa. Journal of Oral Pathology &amp; Medicine2007;36:575‐80. ">Warnakulasuriya 2007</a>). Such a definition is the result of the efforts of an international working group comprising specialists in the ﬁelds of epidemiology, oral medicine, pathology and molecular biology with a special interest in cancer and precancer, who met in London in 2005. This meeting was co‐ordinated by the World Health Organization (WHO) Collaborating Centre for Oral Cancer and Precancer in the UK, to review definitions, classifications, natural history and management of potentially malignant disorders on the basis of previously published work (<a href="./references#CD001829-bbs2-0041" title="AxellT , HolmstrupP , KramerIRH , PindborgJJ . International seminar on oral leukoplakia and associated lesions related to tobacco habits. Community Dentistry and Oral Epidemiology1984;12:145‐54. ">Axell 1984</a>; <a href="./references#CD001829-bbs2-0043" title="AxellT , PindborgJJ , SmithCJ , Van derWaalI . Oral white lesions with special reference to precancerous and tobacco‐related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18‐21, 1994. International Collaborative Group on Oral White Lesions. Journal of Oral Pathology &amp; Medicine1996;25(2):49‐54. [MEDLINE: 1996237276] ">Axell 1996</a>; <a href="./references#CD001829-bbs2-0054" title="KramerIR , LucasRB , PindborgJJ , SobinLH . Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surgery, Oral Medicine and Oral Pathology1978;46(4):518‐39. [MEDLINE: 1979053956] ">Kramer 1978</a>) and new scientific acquisitions. Thus, 'leukoplakia' is a clinical term that is used when the clinician has excluded any other condition of the oral mucosa that can present as a white lesion (e.g. frictional keratosis, lichen planus, white sponge nevus, hairy leukoplakia). Such lesions warrant biopsy and histopathological examination to assess the possible presence of epithelial dysplasia or carcinoma. Leukoplakia is often associated with tobacco smoking or chewing, although idiopathic forms are not rare (<a href="./references#CD001829-bbs2-0042" title="AxellT . Occurrence of leukoplakia and some other oral white lesions among 20,333 adult Swedish people. Community Dentistry and Oral Epidemiology1987;15(1):46‐51. ">Axell 1987</a>). The role of alcohol, viruses and systemic conditions needs further investigation (<a href="./references#CD001829-bbs2-0045" title="DietrichT , ReichartPA , ScheifeleC . Clinical risk factors of oral leukoplakia in a representative sample of the US population. Oral Oncology2004;40(2):158‐63. ">Dietrich 2004</a>; <a href="./references#CD001829-bbs2-0071" title="SyrjänenS , LodiG , vonBültzingslöwenI , AlikoA , ArduinoP , CampisiG , et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Diseases2011;17 Suppl 1:58‐72. ">Syrjänen 2011</a>). </p> <p>Clinical variants of leukoplakia are often classified into two groups: (1) homogeneous leukoplakia, a lesion of uniform flat appearance that may exhibit superficial irregularities, but with consistent texture throughout; and (2) non‐homogeneous leukoplakia, a predominantly white or white and red lesion (erythroleukoplakia) with an irregular texture that may include ulceration and may be characterised by a speckled, nodular or verrucous topography. Histological features of both forms of leukoplakia are variable and may include ortho‐keratosis or para‐keratosis of various degrees, acanthosis or atrophy of the squamous epithelium, mild inflammation in the corium, dysplastic changes of various grades (i.e. mild, moderate or severe), carcinoma in situ or carcinoma. Some cases of predominantly white lesions that are difficult to diagnose, in spite of the availability of a biopsy. </p> <p>Leukoplakia is not uncommon, and although it is highly variable among geographical areas and demographic groups, the prevalence of leukoplakia in the general population varies from less than 1% to more than 5% (<a href="./references#CD001829-bbs2-0041" title="AxellT , HolmstrupP , KramerIRH , PindborgJJ . International seminar on oral leukoplakia and associated lesions related to tobacco habits. Community Dentistry and Oral Epidemiology1984;12:145‐54. ">Axell 1984</a>; <a href="./references#CD001829-bbs2-0042" title="AxellT . Occurrence of leukoplakia and some other oral white lesions among 20,333 adult Swedish people. Community Dentistry and Oral Epidemiology1987;15(1):46‐51. ">Axell 1987</a>; <a href="./references#CD001829-bbs2-0044" title="BouquotJE , GorlinRJ . Leukoplakia, lichen planus, and other oral keratoses in 23,616 white Americans over the age of 35 years. Oral Surgery, Oral Medicine and Oral Pathology1986;61(4):373‐81. ">Bouquot 1986</a>; <a href="./references#CD001829-bbs2-0052" title="IkedaN , IshiiT , IidaS , KawaiT . Epidemiological study of oral leukoplakia based on mass screening for oral mucosal diseases in a selected Japanese population. Community Dentistry and Oral Epidemiology1991;19(3):160‐3. ">Ikeda 1991</a>; <a href="./references#CD001829-bbs2-0062" title="ReichartPA . Oral mucosal lesions in a representative cross‐sectional study of aging Germans. Community Dentistry and Oral Epidemiology2000;28(5):390‐8. ">Reichart 2000</a>). In a systematic review that included studies with more than 1000 individuals, the pooled prevalence was estimated to be between 1.49% and 4.27% (<a href="./references#CD001829-bbs2-0060" title="PettiS . Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncology2003;39:770‐80. ">Petti 2003</a>). Incidence data are very scarce. A study from Japan reported an age‐adjusted incidence rate per 100,000 person‐years of 409.2 among males and 70 among females (<a href="./references#CD001829-bbs2-0059" title="NagaoT , IkedaN , FukanoH , HashimotoS , ShimozatoK , WarnakulasuriyaS . Incidence rates for oral leukoplakia and lichen planus in a Japanese population. Journal of Oral Pathology and Medicine2005;34(9):532‐9. ">Nagao 2005</a>), and an Indian study, conducted in a population with distinctive risk factors for oral cancer, reported lower figures: 240 among males and 3 among females (<a href="./references#CD001829-bbs2-0047" title="GuptaPC , MehtaFS , DaftaryDK , PindborgJJ , BhonsleRB , JalnawallaPN , et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10‐year follow‐up study of Indian villagers. Community Dentistry and Oral Epidemiology1980;8(6):283‐33. ">Gupta 1980</a>). </p> <p>Leukoplakia is one of a group of conditions defined as potentially malignant disorders (i.e. "morphological alterations amongst which some may have an increased potential for malignant transformation, [they] are also indicators of risk of likely future malignancies elsewhere in (clinically normal appearing) oral mucosa and not only site specific predictors") (<a href="./references#CD001829-bbs2-0074" title="WarnakulasuriyaS , JohnsonNW , Van derWaalI . Nomenclature and classification of potentially malignant disorders of the oral mucosa. Journal of Oral Pathology &amp; Medicine2007;36:575‐80. ">Warnakulasuriya 2007</a>). The rate of malignant transformation into squamous cell carcinoma varies from almost 0% to 36.4% (<a href="./references#CD001829-bbs2-0040" title="ArduinoPG , BaganJ , El‐NaggarAK , CarrozzoM . Urban legends series: oral leukoplakia. Oral Diseases2013;19:642‐59. [DOI: 10.1111/odi.12065] ">Arduino 2013</a>), and a study investigating the natural limit of malignant transformation on the basis of European epidemiological data concluded that the upper limit of the annual transformation rate of oral leukoplakia is unlikely to exceed 1% (<a href="./references#CD001829-bbs2-0064" title="ScheifeleC , ReichartPA . Is there a natural limit of the transformation rate of oral leukoplakia?. Oral Oncology2003;39(5):470‐5. ">Scheifele 2003</a>). </p> <p>Non‐homogeneous leukoplakias carry a higher degree of risk of transformation when compared with homogeneous variants. Among patients with a histopathological diagnosis of dysplasia, about 1/10 of the total may be at higher risk. Other reported risk factors of statistical significance for cancer development in people with leukoplakia include female gender, long duration of leukoplakia, non‐smoking status, location on the lateral tongue and/or floor of the mouth, size &gt; 200 mm<sup>2</sup> (<a href="./references#CD001829-bbs2-0050" title="HolmstrupP , VedtofteP , ReibelJ , StoltzeK . Long‐term treatment outcome of oral premalignant lesions. Oral Oncology2006;42(5):461‐74. ">Holmstrup 2006</a>) and the presence of <i>Candida albicans</i> (<a href="./references#CD001829-bbs2-0073" title="Van derWaalI . Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncology2009;45:317‐23. ">Van der Waal 2009</a>). Studies investigating biomarkers and histological features have suggested methods that can be used to identify which patients with leukoplakia will develop oral cancer, and which will not (<a href="./references#CD001829-bbs2-0061" title="PitiyageG , TilakaratneWM , TavassoliM , WarnakulasuriyaS . Molecular markers in oral epithelial dysplasia: review. Journal of Oral Pathology &amp; Medicine2009;38:737‐52. ">Pitiyage 2009</a>; <a href="./references#CD001829-bbs2-0069" title="SmithJ , RattayT , McConkeyC , HelliwellT , MehannaH . Biomarkers in dysplasia of the oral cavity: a systematic review. Oral Oncology2009;45:647‐53. ">Smith 2009</a>); however, a definitive, evidence‐based and clinically useful predictor of malignant transformation for dysplastic and non‐dysplastic leukoplakias is not available at the moment. Aneuploid lesions (i.e. with abnormal DNA content) are more likely to transform to cancer compared with diploid lesions (i.e. with normal DNA content) (<a href="./references#CD001829-bbs2-0070" title="SperandioM , BrownAL , LockC , MorganPR , CouplandVH , MaddenPB , et al. Predictive value of dysplasia grading and DNA ploidy in malignant transformation of oral potentially malignant disorders. Cancer Prevention Research (Philadelphia, Pa.)2013;6:822‐31. ">Sperandio 2013</a>; <a href="./references#CD001829-bbs2-0072" title="Torres‐RendonA , StewartR , CraigGT , WellsM , SpeightPM . DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncology2009;45:468‐73. ">Torres‐Rendon 2009</a>). </p> </section> <section id="CD001829-sec-0032"> <h3 class="title" id="CD001829-sec-0032">Description of the intervention</h3> <p>Most leukoplakias are asymptomatic; therefore, the need for treatment is based primarily on the precancerous nature of the lesion, and the primary aim of management should be to avoid development of cancer. This is particularly important in view of the poor prognosis associated with oral squamous cell carcinoma, in which only about 50% of patients are still alive five years after diagnosis (<a href="./references#CD001829-bbs2-0066" title="ScullyC , BaganJ . Oral squamous cell carcinoma overview. Oral Oncology2009;45:301‐8. ">Scully 2009</a>), and of the morbidity associated with oral cancer and complications of oral cancer therapy (<a href="./references#CD001829-bbs2-0046" title="EpsteinJB , ThariatJ , BensadounRJ , BaraschA , MurphyBA , KolnickL , et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA: A Cancer Journal for Clinicians2012;62:400‐22. ">Epstein 2012</a>). </p> <p>Many approaches to the treatment of leukoplakia have been proposed in an attempt to prevent cancer development and to evaluate clinical/histological resolution of oral leukoplakias (<a href="./references#CD001829-bbs2-0056" title="LodiG , PorterS . Management of potentially malignant disorders: evidence and critique. Journal of Oral Pathology &amp; Medicine2008;37:63‐9. ">Lodi 2008</a>). These approaches include surgical excision with different techniques (scalpel, cryosurgery, photodynamic therapy, laser surgery and vaporisation), medical treatment (topical or systemic), cessation of risk activities (smoking and alcohol) and no intervention but strict surveillance. </p> </section> <section id="CD001829-sec-0033"> <h3 class="title" id="CD001829-sec-0033">How the intervention might work</h3> <p>The rationale of surgical excision is that removing the clinically altered tissue could prevent the onset of oral cancer. For medical treatments, the rationale depends on the mechanism of action of the agent employed: retinoids, vitamin A and carotenoids might influence epithelial turnover; non‐steroidal anti‐inflammatory drugs (NSAIDs) block cyclo‐oxygenase activity, thereby modulating specific prostaglandins possibly involved in carcinogenesis; and chemotherapeutic agents act directly on early neoplastic cells. As many of these treatments have potentially serious adverse effects, the “wait and see” approach, based on strict clinical and histological surveillance, is generally employed to identify early cancer onset and to initiate cancer treatment to render the best possible prognosis. Although surgery and medical treatments aim to remove or reduce the lesion, it must be stressed that no evidence has shown a relationship between changes in size or resolution and decreased risk of oral cancer. </p> </section> <section id="CD001829-sec-0034"> <h3 class="title" id="CD001829-sec-0034">Why it is important to do this review</h3> <p>Cochrane Oral Health undertook an extensive prioritisation exercise in 2014 to identify a core portfolio of titles that were the most clinically important reviews to maintain in <i>The Cochrane Library</i> (<a href="./references#CD001829-bbs2-0076" title="WorthingtonH , ClarksonJ , WeldonJ . Priority oral health research identification for clinical decision‐making. Evidence‐based Dentistry2015;16(3):69‐71. ">Worthington 2015</a>). This review was identified as a priority title by the oral medicine expert panel (<a href="http://ohg.cochrane.org/priority-reviews" target="_blank">Cochrane OHG priority review portfolio</a>). Treatment of leukoplakia continues to be based on expert opinion, and more research is needed. This review aims to provide evidence‐based support for clinicians and patients and a clinical research agenda for planning future studies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001829-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001829-sec-0035"></div> <p>To assess the effectiveness, safety and acceptability of treatments for leukoplakia in preventing oral cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001829-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001829-sec-0036"></div> <section id="CD001829-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001829-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs) comparing effects of surgery, medical or complementary treatments (local or systemic) or risk factor cessation versus placebo. </p> </section> <section id="CD001829-sec-0039"> <h4 class="title">Types of participants</h4> <p>Anyone with a diagnosis of oral leukoplakia (without histopathological evidence of carcinoma) as defined, at the time of the studies, by consensus conferences held in 1978, 1983, 1994 and 2005 (<a href="./references#CD001829-bbs2-0041" title="AxellT , HolmstrupP , KramerIRH , PindborgJJ . International seminar on oral leukoplakia and associated lesions related to tobacco habits. Community Dentistry and Oral Epidemiology1984;12:145‐54. ">Axell 1984</a>; <a href="./references#CD001829-bbs2-0043" title="AxellT , PindborgJJ , SmithCJ , Van derWaalI . Oral white lesions with special reference to precancerous and tobacco‐related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18‐21, 1994. International Collaborative Group on Oral White Lesions. Journal of Oral Pathology &amp; Medicine1996;25(2):49‐54. [MEDLINE: 1996237276] ">Axell 1996</a>; <a href="./references#CD001829-bbs2-0054" title="KramerIR , LucasRB , PindborgJJ , SobinLH . Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surgery, Oral Medicine and Oral Pathology1978;46(4):518‐39. [MEDLINE: 1979053956] ">Kramer 1978</a>, <a href="./references#CD001829-bbs2-0074" title="WarnakulasuriyaS , JohnsonNW , Van derWaalI . Nomenclature and classification of potentially malignant disorders of the oral mucosa. Journal of Oral Pathology &amp; Medicine2007;36:575‐80. ">Warnakulasuriya 2007</a>). </p> </section> <section id="CD001829-sec-0040"> <h4 class="title">Types of interventions</h4> <section id="CD001829-sec-0041"> <h5 class="title">Active</h5> <p> <ul id="CD001829-list-0001"> <li> <p>Surgical removal of the lesion, including surgical excision, laser surgery, cryotherapy</p> </li> <li> <p>Systemic medical treatment</p> </li> <li> <p>Topical medical treatment, including anti‐inflammatory agents, antimycotic agents, carotenoids and retinoids, cytotoxic agents, etc. </p> </li> <li> <p>Removal of predisposing habits (e.g. tobacco, alcohol)</p> </li> <li> <p>Other treatment (e.g. photodynamic therapy)</p> </li> <li> <p>Combined treatment</p> </li> </ul> </p> </section> <section id="CD001829-sec-0042"> <h5 class="title">Control</h5> <p> <ul id="CD001829-list-0002"> <li> <p>Placebo</p> </li> <li> <p>No treatment</p> </li> </ul> </p> </section> </section> <section id="CD001829-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p>In light of the pre‐cancerous nature of leukoplakia, the primary objective of treatment is to prevent cancer development. </p> <section id="CD001829-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001829-list-0003"> <li> <p>Oral cancer development, demonstrated by histopathological examination</p> </li> </ul> </p> </section> <section id="CD001829-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001829-list-0004"> <li> <p>Clinical resolution, in terms of the proportion of lesions that did not resolve (with relapse data when provided) </p> </li> <li> <p>Improvement of histological features, in terms of the proportion of lesions that did not show improvement in histological features </p> </li> <li> <p>Safety of the intervention, as measured by the incidence of adverse effects</p> </li> </ul> </p> </section> </section> </section> <section id="CD001829-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <p>To identify studies included in or considered for this review, we developed detailed search strategies for each database searched. These were based on the search strategy developed for MEDLINE Ovid but revised appropriately for each database. The search strategy used a combination of controlled vocabulary and free text terms and was linked with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised controlled trials (RCTs) in MEDLINE: sensitivity‐maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in Box 6.4.c of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Version 5.1.0 (updated March 2011) (<a href="./references#CD001829-bbs2-0048" title="HigginsJPT , DeeksJJ , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Chichester, UK: John Wiley &amp; Sons, Ltd, 2011. ">Higgins 2011</a>)<i>.</i> We have provided details of the MEDLINE search in <a href="./appendices#CD001829-sec-0123">Appendix 1</a>. </p> <section id="CD001829-sec-0047"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases.</p> <p> <ul id="CD001829-list-0005"> <li> <p>Cochrane Oral Health's Trials Register (to 16 May 2016) (see <a href="./appendices#CD001829-sec-0124">Appendix 2</a>); </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) (<i>the Cochrane Library</i>, 2016, Issue 4) (see <a href="./appendices#CD001829-sec-0125">Appendix 3</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to 16 May 2016) (see <a href="./appendices#CD001829-sec-0123">Appendix 1</a>); </p> </li> <li> <p>Embase Ovid (1980 to 16 May 2016) (see <a href="./appendices#CD001829-sec-0126">Appendix 4</a>); </p> </li> <li> <p>CancerLit via PubMed (1950 to 16 May 2016) (see <a href="./appendices#CD001829-sec-0127">Appendix 5</a>). </p> </li> </ul> </p> <p>We placed no restrictions on the language or date of publication when searching the electronic databases. </p> </section> <section id="CD001829-sec-0048"> <h4 class="title">Searching other resources</h4> <p>We searched the following databases for ongoing trials (see <a href="./appendices#CD001829-sec-0128">Appendix 6</a> for details of the search strategy). </p> <p> <ul id="CD001829-list-0006"> <li> <p><a href="http://www.isrctn.com/page/mrct" target="_blank">metaRegister of Controlled Trials</a> (to 10 February 2015); </p> </li> <li> <p><a href="http://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a> (to 16 May 2016); </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/default.aspx" target="_blank">The WHO International Clinical Trials Registry Platform</a> (to 16 May 2016). </p> </li> </ul> </p> <p>We manually checked the reference lists of included studies and existing reviews. The metaRegister of Controlled Trials is no longer available and so was not searched in May 2016. </p> </section> </section> <section id="CD001829-sec-0049"> <h3 class="title" id="CD001829-sec-0049">Data collection and analysis</h3> <section id="CD001829-sec-0050"> <h4 class="title">Selection of studies</h4> <p>Two review authors (GL and RF) separately examined the title and abstract of each article identified by the different search strategies. When at least one review author considered the article relevant, it progressed in the review process and was included in a digital archive prepared by using dedicated software. We obtained full reports for all relevant studies. </p> </section> <section id="CD001829-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>All studies meeting the inclusion criteria underwent data extraction performed by at least two review authors, using a specially designed form. We present the characteristics of trial participants, interventions and outcomes for the included trials in the <a href="./references#CD001829-sec-0141" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD001829-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias of included trials and resolved disagreements through discussion and consensus. We used the recommended approach for assessing risk of bias in studies included in Cochrane reviews (<a href="./references#CD001829-bbs2-0049" title="HigginsJPT , DeeksJJ , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 8: Assessing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Chichester, UK: John Wiley &amp; Sons, Ltd, 2011. ">Higgins 2011a</a>). This approach addresses the following seven specific domains. </p> <p> <ul id="CD001829-list-0007"> <li> <p>Random sequence generation (selection bias)</p> </li> <li> <p>Allocation concealment (selection bias)</p> </li> <li> <p>Blinding of participants and personnel (performance bias)</p> </li> <li> <p>Blinding of outcome assessment (detection bias)</p> </li> <li> <p>Incomplete outcome data (attrition bias)</p> </li> <li> <p>Selective reporting (reporting bias)</p> </li> <li> <p>Other bias</p> </li> </ul> </p> <p>Each domain in the tool includes one or more specific entries in a ‘Risk of bias’ table. Within each entry, the first part of the tool describes what was reported to have happened in the study, in sufficient detail to support a judgement about risk of bias. The second part of the tool assigns a judgement related to the risk of bias for that entry ‐ ‘low risk’, ‘high risk’ or ‘unclear risk’. After taking into account the additional information provided by trial authors, we summarised the risk of bias in included studies as follows. </p> <p> <ul id="CD001829-list-0008"> <li> <p>Low risk of bias: low risk of bias for all key domains</p> </li> <li> <p>Unclear risk of bias: unclear risk of bias for one or more key domains</p> </li> <li> <p>High risk of bias: high risk of bias for one or more key domains</p> </li> </ul> </p> <p>We completed a 'Risk of bias' table for each included study (see <a href="./references#CD001829-sec-0141" title="">Characteristics of included studies</a>) and presented results graphically by study (<a href="#CD001829-fig-0001">Figure 1</a>) and by domain over all studies (<a href="#CD001829-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD001829-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD001829-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD001829-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001829-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> </section> <section id="CD001829-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <p>The primary measure of intervention effect was onset of oral cancer. Dichotomous data were reported for this outcome measure: cancer development versus absence of cancer development. </p> <p>Secondary outcomes, clinical resolution, histological changes and adverse effects were usually reported as ordinal measures. We dichotomised data: clinical resolution vs partial or no clinical response; decreased severity vs worsening of histology or no change in histological features. </p> <p>For each intervention, we sought and summarised data on the number of participants from both intervention and control groups who experienced the event (outcome) and the total number of participants. We analysed dichotomous data by calculating risk ratios. As we anticipated pooling data from studies in which true treatment effects were likely to differ, we planned to use a random‐effects model in statistical analyses; however, we used a fixed‐effect model because of the very small number of studies combined. </p> </section> <section id="CD001829-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>The individual participant was the unit of analysis.</p> </section> <section id="CD001829-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>Whenever possible, we obtained missing data from tables and graphs or through personal contact with study authors. When this was not possible, and we found no evidence that data were missing because of a specific bias, we analysed only available data (<a href="./references#CD001829-bbs2-0048" title="HigginsJPT , DeeksJJ , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Chichester, UK: John Wiley &amp; Sons, Ltd, 2011. ">Higgins 2011</a>). This represents a change from the previous version of the review, in which missing data were imputed with the assumption that all were poor outcomes. </p> </section> <section id="CD001829-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the significance of discrepancies in the estimates of treatment effects provided by different trials by using Cochran’s test for heterogeneity and the I² statistic; the latter describes the percentage total variation across studies that is due to heterogeneity rather than to chance. Heterogeneity was considered statistically significant if the P value was less than 0.1. A rough guide to the interpretation of I² given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> is as follows: 0 to 40% might not be important, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, 75% to 100% represents very substantial ('considerable') heterogeneity (<a href="./references#CD001829-bbs2-0048" title="HigginsJPT , DeeksJJ , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. Chichester, UK: John Wiley &amp; Sons, Ltd, 2011. ">Higgins 2011</a>). </p> </section> <section id="CD001829-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to minimise reporting biases by conducting a thorough search of multiple sources including trial registries, and by making efforts to identify unpublished trials and non‐English language publications. </p> </section> <section id="CD001829-sec-0058"> <h4 class="title">Data synthesis</h4> <p>When valid and relevant data were collected, we undertook a meta‐analysis of the data. We grouped and analysed studies on the basis of intervention category. We conducted meta‐analyses in Review Manager software, using the Mantel‐Haenszel method with a fixed‐effect model. We had planned to use a random‐effects model, but this would not have been appropriate because of the small number of studies included. We did not pool data when substantial heterogeneity was identified. </p> </section> <section id="CD001829-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We had planned to conduct subgroup analyses for smoking and non‐smoking participants, and for lesions with or without dysplasia. Unfortunately, as such data were not available, we did not perform subgroup analyses. </p> </section> <section id="CD001829-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We had planned to undertake sensitivity analysis excluding studies at high risk and at unclear risk of bias. </p> <section id="CD001829-sec-0061"> <h5 class="title">Summarising findings and assessing the quality of the evidence</h5> <p>We constructed 'Summary of findings' tables for each comparison to present the results for our review outcomes. We assessed the quality of the evidence using GRADE (Grades of Recommendation, Assessment, Development and Evaluation Working Group) criteria. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001829-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001829-sec-0062"></div> <section id="CD001829-sec-0063"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD001829-sec-0141" title="">Characteristics of included studies</a>, <a href="./references#CD001829-sec-0142" title="">Characteristics of excluded studies</a> and <a href="./references#CD001829-sec-0144" title="">Characteristics of ongoing studies</a>. </p> <section id="CD001829-sec-0064"> <h4 class="title">Results of the search</h4> <p>This review was originally published in 2001, and updates were published in 2004 and 2006. Since its first publication up until May 2016, we have identified a total of 3438 articles through the search strategy. We have examined titles and abstracts for eligibility and have eliminated those not matching the inclusion criteria. We identified 68 apparently eligible studies and rejected 30 because they were not pertinent. Nine of the studies are ongoing (see <a href="./references#CD001829-sec-0144" title="">Characteristics of ongoing studies</a> for details). After we obtained the full‐text version of the remaining 29 studies, we excluded 13 additional studies (<a href="./references#CD001829-sec-0142" title="">Characteristics of excluded studies</a>) ‐ one because it was quasi‐randomised, four because of inadequate allocation, four for problems in selection of participants and four for lack of an adequate control group. We categorised two studies as awaiting classification (<a href="./references#CD001829-bbs2-0028" title="CalifanoJA , FerrisRL , EpsteinJB , GillespieMB , FeldmanLE , GibsonMK , et al. A phase II trial of cetuximab in high‐risk premalignant lesions of the upper aerodigestive tract. Journal of Clinical Oncology2012;30(No 15_suppl (May 20 Suppl)):5528. ">Califano 2012</a>; <a href="./references#CD001829-bbs2-0029" title="ChibaI , TakeshimaM , AbikoY , KobayashiH , MuthumalaM , SugiuraC , et al. Curcumin is an effective chemopreventive substance for betel quid chewer's oral precancer in Sri Lanka. Cancer Prevention Research2012;5(11 Suppl 1):PR‐04. [DOI: 10.1158/1940‐6207.PREV‐12‐PR‐04] ">Chiba 2012</a>; <a href="./references#CD001829-sec-0143" title="">Characteristics of studies awaiting classification</a>). Thus we included 14 studies in this review. See <a href="#CD001829-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD001829-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD001829-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD001829-sec-0065"> <h4 class="title">Included studies</h4> <section id="CD001829-sec-0066"> <h5 class="title">Characteristics of trial setting and design</h5> <section id="CD001829-sec-0067"> <h6 class="title">Location</h6> <p>Of the 15 studies included, six were conducted in the USA (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>), three in India (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>), one in Italy (<a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>), two in China (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>), one in Canada (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>) and one in Japan (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>). The setting for all studies was a university hospital. </p> </section> <section id="CD001829-sec-0068"> <h6 class="title">Design</h6> <p>Ten trials had a two‐arm parallel design (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>); three, a three‐arm parallel design (<a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>); and one, a four‐arm parallel design (<a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). In three of the four studies with more than two arms, we pooled together data from the active arms: interventions differed in dosage in <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; and <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>. </p> </section> <section id="CD001829-sec-0069"> <h6 class="title">Duration</h6> <p>The trials varied in length. Three studies used an open follow‐up (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>); one study lasted two years (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>); and all other studies lasted less than one year. </p> </section> <section id="CD001829-sec-0070"> <h6 class="title">Funding</h6> <p>Two trials did not specify any funding source (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>). In two trials, some study authors worked for the company that supplied the study drug (<a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>); in another, the first study author had ownership interest in the patent of the drug tested (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>). One study was supported by Central Soya Company and NIH (National Institutes of Health) (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>), one by Hoffmann‐La Roche and the National Cancer Institute (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>), one by the Chinese National Natural Science Foundation (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>), one by NIH (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>), one by the National Cancer Institute Specialized Programs of Reasearch Excellence (SPORE) Program (<a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>), one by the Butterfield Award of the Sasakawa Foundation GB and DSM Nutrition Japan (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>), one by Pfizer (<a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>), one by the Italian National Research Council (CNR) and the Italian Ministry of University, Research, Science and Technology (MURST) (<a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>), one by Jagsonpal Pharmaceuticals Ltd., New Delhi, India (<a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>), one by the National Cancer Institute of Canada (<a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>), one by the Beijing Natural Science Foundation, the National Natural Science Foundation of China and the Tenth 5‐Year Plan of National Key Technologies R&amp;D Program in China and NIH (<a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>) and one by Ito En Ltd. (<a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). </p> </section> </section> <section id="CD001829-sec-0071"> <h5 class="title">Characteristics of participants</h5> <p>The total number of participants randomised in the trials was 909, with a mean of 64.9 participants per study (ranged from 10 to 131 participants). </p> <p>The reported proportion of smoking and drinking participants (the two main risk factors for oral cancer) varied from 8% (<a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>) to 86% (<a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>), and from 9% (<a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>) to 71% (<a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>), respectively. Use of tobacco products (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>) and smoking (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>) were exclusion criteria in two studies. None of the study authors reported significant changes in these habits during the course of the trial. In two studies, all participants recruited were chewers of tobacco‐containing betel quid (another well‐known risk factor for oral cancer) from the same Indian village (Trivandrum, Kerala) (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>). All participants enrolled in the studies underwent a confirmatory biopsy; however, only four studies reported the histological criteria employed (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>). Seven studies reported the percentage of dysplastic lesions, which ranged from 18.75% (<a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>) to 73.2% (<a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>) (see <a href="#CD001829-tbl-0007">Table 1</a>). One study excluded lesions with severe dysplasia (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>), and another study included cases with at least one of the following features: at least mild dysplasia, high‐risk location, significant extent of tissue involvement and presence of symptoms (<a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). </p> <div class="table" id="CD001829-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participants with dysplastic leukoplakia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants with dysplastic leukoplakia (any grade)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.75%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.2%</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD001829-sec-0072"> <h5 class="title">Characteristics of interventions</h5> <p>We did not identify any RCTs that compared surgical treatments with placebo or no treatment, nor did we identify any RCTs of risk factor cessation. All included trials compared medical or complementary treatment versus placebo, usually a preparation similar to the treatment, without the active ingredient; in one case, the placebo contained vitamin C, which we considered an inactive ingredient (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>). </p> <p>Four RCTs compared topical treatment versus placebo (129 participants) (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>), and nine RCTs compared systemic treatment versus placebo (716 participants) (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). One RCT compared a combination of topical and systemic treatments versus placebo (64 participants) (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>). </p> <p>Four studies tested vitamin A or retinoids (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>); three studies tested beta carotene or carotenoids (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>); two studies tested NSAIDs: ketorolac (<a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>) and celecoxib (<a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>); and four studies tested herbal extracts, in particular, tea components (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a> ‐ mixed; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a> ‐ green tea extract capsules), a Chinese herbal mixture (<a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>) and gel containing freeze‐dried black raspberries (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>). The other interventions tested were bleomycin (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>) and Bowman‐Birk inhibitor (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>). </p> </section> <section id="CD001829-sec-0073"> <h5 class="title">Characteristics of outcomes</h5> <p>Five studies reported data on oral cancer development (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). In Epstein's trial, although seven out of 12 participants in the control group received the active treatment at the end of the study period, we conducted an intention‐to‐treat (ITT) analysis for this review. </p> <p>All studies used lesion measurement as the clinical parameter to assess change; five studies also used pictures of the lesions for clinical evaluation (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>; <a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>). In 11 RCTs, a complete response was defined as complete disappearance of the lesion (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>), lasting at least four weeks in four of them (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>). For partial response, nine studies used the definition 'greater than 50% reduction', and one used a slightly different criterion ‐ 'greater than 30% reduction' (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>). Three studies defined “stable disease” as a reduction of less than 50% of the lesion (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>); three studies adopted an otherwise non‐specified "unchanged clinical aspect" (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>); and two studies defined "stable disease" as lesions not satisfying any other category (<a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). Eight studies gave similar definitions of "disease progression" as an increase in the size of the lesion or the appearance of new lesions (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). One study included the "no response" category, indicating stable and progressive lesions (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>). Three studies adopted different categories for clinical evaluation. <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a> used the following: remission, no change, new leukoplakia. <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> used positive response (including complete and partial response), stable disease and progressive disease. One study reported the change in lesion measurement, expressed in mm<sup>2</sup> (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>). Clinical response was recorded immediately at the end of treatment in 10 studies (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>), two weeks after the end of treatment in <a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a> and three months after the end of treatment in <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>. In two studies, it was not clear when the reported clinical assessment was recorded (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>). </p> <p>Six studies reported assessment of histological changes (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). These studies did not use a unique histological classification, and the comparison between pre‐treatment and post‐treatment histological features was highly variable. One study defined histological response as an otherwise non‐specified "reversal" or "improvement" of dysplastic features (<a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>); another adopted a graphical method for evaluating histological changes (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>). <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a> reported histological changes in the treatment group only. In one study, a control biopsy was taken only if development of cancer was suspected (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>). </p> <p>Biomarkers evaluated included bcl‐2 immunostaining (<a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>), AgNOR (silver‐stained nucleolar organizer region) and PCNA (proliferation cell nuclear antigen) labelling indexes (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>), biomarkers of DNA damage in exfoliated cells and peripheral blood lymphocytes (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>), Neu protein of exfoliated cells and serum (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>), epidermal growth factor receptors (EGFRs) (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>) and p53 and Ki67 (protein; cellular marker of neoplasia) (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>). </p> <p>Most trials monitored safety of the intervention. Only <a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a> and <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> did not appear to measure adverse effects. </p> </section> </section> <section id="CD001829-sec-0074"> <h4 class="title">Excluded studies</h4> <p>The primary reason for exclusion of each study is given in the <a href="./references#CD001829-sec-0142" title="">Characteristics of excluded studies</a> table. Many trials were ineligible for more than one reason; however, the more common reasons for exclusion were inappropriate selection of participants, lack of random allocation and absence of a proper control arm. In particular, although we found three randomised controlled trials evaluating surgical interventions (<a href="./references#CD001829-bbs2-0017" title="CheeM , SasakiC . Carbon dioxide laser fiber for the excision of oral leukoplakia. Annals of Otology, Rhinology, and Laryngology2013;122:547‐9. ">Chee 2013</a>; <a href="./references#CD001829-bbs2-0024" title="López‐JornetP , Camacho‐AlonsoF . Comparison of pain and swelling after removal of oral leukoplakia with CO₂ laser and cold knife: a randomized clinical trial. Medicina Oral, Patologia Oral y Cirugia Bucal2013;18:38e‐44e. ">López‐Jornet 2013</a>; <a href="./references#CD001829-bbs2-0026" title="SchwarzF , MarakiD , YalcinkayaS , BielingK , BockingA , BeckerJ . Cytologic and DNA‐cytometric follow‐up of oral leukoplakia after CO2‐ and Er:YAG‐laser assisted ablation: a pilot study. Lasers in Surgery and Medicine2005;37(1):29‐36. ">Schwarz 2005</a>), we were unable to include them in the review as they did not include a no treatment or placebo group. </p> </section> </section> <section id="CD001829-sec-0075"> <h3 class="title">Risk of bias in included studies</h3> <p>On the basis of criteria used in the critical appraisal of studies, one study had an overall low risk of bias (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>). We judged seven studies as having unclear risk of bias (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>; <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>; <a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). We considered the remaining studies to be at high risk of bias (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>). See <a href="#CD001829-fig-0001">Figure 1</a> and <a href="#CD001829-fig-0002">Figure 2</a>. </p> <section id="CD001829-sec-0076"> <h4 class="title">Allocation</h4> <p>We assessed the generation of the randomisation sequence as having low risk of bias for six trials and unclear risk for eight trials. </p> <p>We assessed the concealment of allocation as having low risk of bias for three trials, at unclear risk for 10 trials and at high risk for one trial (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>). In <a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>, the block size was two. </p> </section> <section id="CD001829-sec-0077"> <h4 class="title">Blinding</h4> <p>We assessed blinding of participants and personnel, as well as blinding of outcome assessment, as low risk of bias for 11 trials and unclear risk for four studies in which not enough information was provided. </p> </section> <section id="CD001829-sec-0078"> <h4 class="title">Incomplete outcome data</h4> <p>The reported drop‐out rate ranged from 0% (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>) to 32.5% (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>). We assessed 11 trials as having low risk of bias with regard to attrition bias because they reported there were no drop‐outs, or because drop‐out was not likely to influence findings. We assessed three studies with high drop‐out rates as having high risk of bias (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>). </p> </section> <section id="CD001829-sec-0079"> <h4 class="title">Selective reporting</h4> <p>Most trials reported important outcomes and were assessed as having low risk of bias. Five studies failed to report histological results (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>; <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>); we assessed these trials as having high risk of bias for this domain. </p> </section> <section id="CD001829-sec-0080"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed <a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>, which had discrepant published and unpublished data, along with baseline imbalance, as having unclear risk of bias for this domain. See <a href="#CD001829-fig-0002">Figure 2</a>. </p> </section> </section> <section id="CD001829-sec-0081"> <h3 class="title" id="CD001829-sec-0081">Effects of interventions</h3> <p>See: <a href="./full#CD001829-tbl-0001"><b>Summary of findings for the main comparison</b> Vitamin A or retinoids versus placebo for treating oral leukoplakia</a>; <a href="./full#CD001829-tbl-0002"><b>Summary of findings 2</b> Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia</a>; <a href="./full#CD001829-tbl-0003"><b>Summary of findings 3</b> Non‐steroidal anti‐inflammatory drugs (NSAIDs) vs placebo for treating oral leukoplakia</a>; <a href="./full#CD001829-tbl-0004"><b>Summary of findings 4</b> Herbal extracts vs placebo for treating oral leukoplakia</a>; <a href="./full#CD001829-tbl-0005"><b>Summary of findings 5</b> Topical bleomycin vs placebo for treating oral leukoplakia</a>; <a href="./full#CD001829-tbl-0006"><b>Summary of findings 6</b> Bowman‐Birk inhibitor versus placebo for oral leukoplakia</a> </p> <section id="CD001829-sec-0082"> <h4 class="title">Vitamin A and retinoids versus placebo</h4> <p>Four studies (one at high, two at unclear and one at low risk of bias) compared vitamin A and retinoids versus placebo. Three of these studies evaluated systemic treatment (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>), and one evaluated topical treatment (<a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>). </p> <section id="CD001829-sec-0083"> <h5 class="title">Oral cancer development</h5> <p>One study reported effects of systemic vitamin A on cancer incidence (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>). Investigators found no evidence of benefit compared with placebo (risk ratio (RR) 0.11, 95% confidence interval (CI) 0.01 to 2.05; 85 participants) (<a href="./references#CD001829-fig-0008" title="">Analysis 1.1</a>; <a href="#CD001829-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD001829-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.1 Cancer development" data-id="CD001829-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.1 Cancer development </p> </div> </div> </div> </section> <section id="CD001829-sec-0084"> <h5 class="title">Clinical resolution</h5> <p>Five studies reported effects of vitamin A or retinoids on clinical features of leukoplakia, in particular, on its resolution (<a href="./references#CD001829-fig-0009" title="">Analysis 1.2</a>; <a href="#CD001829-fig-0005">Figure 5</a>). In particular, three studies tested systemic treatment (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>), but because heterogeneity was high (I<sup>2</sup> = 94%), it was inappropriate to combine findings in a meta‐analysis. Two of the three studies at high or unclear risk of bias showed some benefit (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>: RR 0.51, 95% 0.37 to 0.71; 85 participants; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>: RR 0.44, 95% CI 0.27 to 0.73; 54 participants), but <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>, which was at low risk of bias, showed no clear evidence of benefit (RR 0.92, 95% CI 0.78 to 1.08; 40 participants). </p> <div class="figure" id="CD001829-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.2 Oral lesion not completely resolved" data-id="CD001829-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.2 Oral lesion not completely resolved </p> </div> </div> </div> <p><a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a> provided relapse data: nine out of 16 (56%) participants who responded to treatment (partially or completely) subsequently relapsed (no information was available regarding the two partial responders from the placebo group). <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> reported that 14 out of 22 (64%) complete responders developed recurrent lesions (no information was available regarding the three complete responders in the placebo group). </p> <p>One study at unclear risk of bias tested topical treatment (nine participants) and found treatment was not more likely to completely resolve the lesion than placebo: RR 0.83, 95% CI 0.48 to 1.44 (<a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>). </p> <p>In <a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>, one out of five (20%) participants responding completely or partially to the experimental treatment relapsed, and one out of four (25%) participants responding to placebo relapsed. </p> </section> <section id="CD001829-sec-0085"> <h5 class="title">Improvement of histological features</h5> <p>A single study recorded histological improvement and showed that improvement in histological features of lesions was more likely in participants treated with systemic retinoic acid than in those treated with placebo (RR 0.43, 95% CI 0.24 to 0.76; 39 participants; <a href="./references#CD001829-fig-0010" title="">Analysis 1.3</a>) (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>). </p> </section> <section id="CD001829-sec-0086"> <h5 class="title">Safety</h5> <p>Topical 13‐cis‐retinoic acid (<a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a>) and 200,000 IU per week of vitamin A (<a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>) produced no adverse effects. Systemic 13‐cis‐retinoic acid (1 to 2 mg/kg/d) (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>) caused adverse effects of varying severity in 79% of participants (see <a href="#CD001829-tbl-0008">Table 2</a>). Two participants withdrew from <a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a> because of severe conjunctivitis and hypertriglyceridaemia. </p> <div class="table" id="CD001829-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants reporting adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Active treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bowman Birk inhibitor concentrate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 reported from 33 of 67 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 reported from 25 of 65 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical bleomycin vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleomycin group ‐ erythema and erosion (100%), discomfort (60%)</p> <p>Placebo group ‐ erythema only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic 13‐cis‐retinoic acid (from 1 to 2 mg/kg per day) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cheilitis, facial erythema, dryness and peeling of skin, conjunctivitis, hypertriglyceridaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic and topical tea vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured or reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Freeze‐dried black raspberry gel vs placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No participant experienced any treatment‐associated complications"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketorolac oral rinse vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain, toxicity grade 1 and 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta carotene and vitamin C vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No untoward side effects were noted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Celecoxib vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 reported from 32 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 reported from 18 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 participants presented grade 3 adverse events: 2 in placebo arm and 2 in active treatment arm. 2 participants from intervention groups discontinued treatment owing to adverse effects (1 grade 2 and 1 grade 3). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical 13‐cis‐retinoic acid vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No side effects from the use of the gel<br/> were ever observed" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin A (300,000 IU per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache, muscular pain, dry mouth</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta carotene (360 mg per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache, muscular pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lycopene (8 mg or 4 mg) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No side effects, toxicity of any sort were encountered in the complete duration of the therapy" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin A (200,000 IU per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The administered doses of vitamin A did not produce any detectable adverse<br/> effects during the trial period" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese herbal mixture vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured or reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green tea extract at different doses (500, 750 or 1000 mg/m<sup>2</sup> daily) vs placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 to 2 adverse events including insomnia, headache, nausea and nervousness</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>vs = versus</p> </div> </div> </section> </section> <section id="CD001829-sec-0087"> <h4 class="title">Beta carotene or carotenoids versus placebo</h4> <p>Three studies compared systemic beta carotene or carotenoids versus placebo (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>). </p> <section id="CD001829-sec-0088"> <h5 class="title">Oral cancer development</h5> <p>Two studies reported the effects of systemic beta carotene on cancer incidence (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>). Investigators found no evidence of benefit when compared with placebo (RR 0.71, 95% CI 0.24 to 2.09; 132 participants; I<sup>2</sup> = 0%; <a href="./references#CD001829-fig-0011" title="">Analysis 2.1</a>; <a href="#CD001829-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD001829-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.1 Cancer development" data-id="CD001829-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.1 Cancer development </p> </div> </div> </div> </section> <section id="CD001829-sec-0089"> <h5 class="title">Clinical resolution</h5> <p>Three studies tested effects of systemic beta carotene and carotenoids on clinical resolution (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>) (<a href="./references#CD001829-fig-0012" title="">Analysis 2.2</a>; <a href="#CD001829-fig-0007">Figure 7</a>). Owing to high heterogeneity (I<sup>2</sup> = 87%), it was not appropriate to combine findings in a meta‐analysis. Two of the individual studies, which were at unclear risk of bias, found that systemic beta carotene was more effective than placebo for complete resolution of the lesion (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>: RR 0.72, 95% CI 0.58 to 0.90; 89 participants; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>: RR 0.61, 95% CI 0.47 to 0.80; 58 participants). The other study, at high risk of bias, failed to show evidence of benefit (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>: RR 0.95, 95% CI 0.84 to 1.08; 43 participants). </p> <div class="figure" id="CD001829-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.2 Oral lesion not completely resolved" data-id="CD001829-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.2 Oral lesion not completely resolved </p> </div> </div> </div> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> reported that eight out of 15 (54%) complete responders developed recurrent lesions (no information was available regarding the three complete responders in the placebo group). </p> </section> <section id="CD001829-sec-0090"> <h5 class="title">Improvement of histological features</h5> <p>Evidence of histological improvement was recorded when lycopene (a carotenoid) was compared with placebo (RR 0.24, 95% CI 0.12 to 0.46; one study; 58 participants; <a href="./references#CD001829-fig-0013" title="">Analysis 2.3</a>) (<a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>). </p> </section> <section id="CD001829-sec-0091"> <h5 class="title">Safety</h5> <p>Systemic treatment with beta‐carotene produced no adverse effects in one study supplementing 10 mg/d (<a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>). It caused adverse effects of varying severity in 9% of participants in another study supplementing 360 mg/wk (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>). Researchers reported no adverse effects among participants treated with systemic lycopene (<a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>). See <a href="#CD001829-tbl-0008">Table 2</a>. </p> </section> </section> <section id="CD001829-sec-0092"> <h4 class="title">Non‐steroidal anti‐inflammatory drugs (NSAIDs) versus placebo</h4> <p>Two studies at unclear risk of bias compared NSAIDs ‐ ketorolac in <a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a> and celecoxib in <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a> ‐ versus placebo. </p> <section id="CD001829-sec-0093"> <h5 class="title">Oral cancer development</h5> <p>Cancer development was among the outcomes reported in <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008.</a> This did not occur in either arm, probably because of the extremely short duration of the study (12 weeks). </p> </section> <section id="CD001829-sec-0094"> <h5 class="title">Clinical resolution</h5> <p>Investigators found no evidence of benefit for systemic celecoxib (<a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>: RR 0.94, 95% CI 0.83 to 1.08; 46 participants) nor topical ketorolac (<a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>: RR 0.94, 95% CI 0.81 to 1.10; 56 participants) compared with placebo in terms of clinical resolution of lesions (<a href="./references#CD001829-fig-0014" title="">Analysis 3.1</a>). </p> </section> <section id="CD001829-sec-0095"> <h5 class="title">Improvement of histological features</h5> <p>Histological changes were not among the outcomes in the studies testing NSAIDs.</p> </section> <section id="CD001829-sec-0096"> <h5 class="title">Safety</h5> <p>In <a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>, which tested systemic celecoxib, trialists reported that the treatment was "safe and well tolerated". Thirty‐two intervention participants reported 56 adverse effects, and 20 placebo participants reported 20 adverse effects. Minor adverse events included dizziness, diarrheoa and abdominal pain. No participants had grade 4 adverse events. Four participants (two from the placebo group and two from an intervention group) had grade 3 adverse events. Two people discontinued treatment due to an adverse event (grade 2 vision abnormality and hypertension in a participant receiving 400 mgtwice daily of celecoxib and a grade 3 ischemic cerebrovascular accident in a participant receiving 200 mg twice daily of celecoxib. </p> <p>Ketorolac oral rinse caused adverse effects of varying severity in 29% of participants (see <a href="#CD001829-tbl-0008">Table 2</a>). One person withdrew from the trial after the first dose because of mouth pain. </p> </section> </section> <section id="CD001829-sec-0097"> <h4 class="title">Herbal extracts versus placebo</h4> <p>Four studies compared herbal extracts, in particular, tea components (<a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>), a Chinese herbal mixture (<a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>) and freeze‐dried black raspberry gel (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>), versus placebo. </p> <section id="CD001829-sec-0098"> <h5 class="title">Oral cancer development</h5> <p>Cancer development was among the outcomes in <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>; however, it was not possible to analyse data because trial authors reported the cumulative number of cases, without specifying the allocation arm. </p> </section> <section id="CD001829-sec-0099"> <h5 class="title">Clinical resolution</h5> <p>The four studies testing herbal extracts included clinical resolution among outcomes (<a href="./references#CD001829-fig-0015" title="">Analysis 4.1</a>). </p> <p>Systemic treatment with green tea extract showed no evidence of benefit in terms of clinical resolution of leukoplakia when compared with the control in one study at unclear risk of bias (<a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>: RR 0.99, 95% CI 0.86 to 1.14; 39 participants). <a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>, which was at high risk of bias, investigated a treatment integrating systemic (capsules containing 0.38 g of dried mixture of the whole water extract of green tea, green tea polyphenols and tea pigments) and topical preparations of mixed tea extract (mixed tea in glycerin at the concentration of 10%), but was not able to demonstrate benefit when compared with placebo in terms of clinical resolution (RR 1.00, 95% CI 0.94 to 1.07; 59 participants). </p> <p>In one study investigating effects of a Chinese herbal mixture, it was not possible to extract data on clinical resolution (<a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a>). </p> <p>One topical herbal treatment (freeze‐dried black raspberries) showed no evidence of benefit when compared with placebo in a study that was at unclear risk of bias (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>: RR 4.13, 95% CI 0.21 to 80.91; 40 participants). Among participants who did respond to such treatment, six of 22 (32%) in the treatment arm and seven of 17 (41%) in the placebo arm had visible evidence of lesion recurrence at former treatment sites at three months post trial follow‐up (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>). </p> </section> <section id="CD001829-sec-0100"> <h5 class="title">Improvement of histological features</h5> <p>In two studies reporting histological changes, neither active treatment (topical freeze‐dried black raspberries and systemic green tea extract) showed benefit when compared with placebo (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>: RR 0.97, 95% CI 0.58 to 1.60; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>: RR 0.86, 95% CI 0.66 to 1.13; <a href="./references#CD001829-fig-0016" title="">Analysis 4.2</a>). </p> </section> <section id="CD001829-sec-0101"> <h5 class="title">Safety</h5> <p>People undergoing treatment with green tea reported very high frequency (93%) of adverse effects of varying severity in one study (<a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>). Adverse effects were not mentioned in <a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a>. Freeze‐dried black raspberry gel caused no adverse effects (<a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a>). <a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> stated, "drug toxicity was not monitored in the clinical trial". See <a href="#CD001829-tbl-0008">Table 2</a>. </p> </section> </section> <section id="CD001829-sec-0102"> <h4 class="title">Topical bleomycin versus placebo</h4> <p>Topical bleomycin was tested against placebo in a single small study at unclear risk of bias that included 22 participants (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>). Following post‐treatment biopsy, seven participants in the placebo group were crossed over to receive the active intervention. An ITT analysis was conducted for outcomes measured after post‐treatment biopsy. </p> <p>Mean follow‐up from the end of the study was 15 months for group A and 22 months for group B. </p> <section id="CD001829-sec-0103"> <h5 class="title">Oral cancer development</h5> <p>The trial found no evidence of benefit of topical bleomycin compared with placebo in reducing cancer development among participants affected by leukoplakia (RR 3.00, 95% CI 0.32 to 27.83; 20 participants; <a href="./references#CD001829-fig-0017" title="">Analysis 5.1</a>). </p> </section> <section id="CD001829-sec-0104"> <h5 class="title">Clinical resolution</h5> <p>Topical bleomycin showed no benefit for clinical resolution when compared with placebo: RR 0.55, 95% CI 0.29 to 1.04. In addition, among participants for whom follow‐up information was available, two out of four (50%) participants with a complete response relapsed and one out of two (50%) participants with a partial response relapsed (<a href="./references#CD001829-fig-0018" title="">Analysis 5.2</a>). </p> </section> <section id="CD001829-sec-0105"> <h5 class="title">Improvement of histological features</h5> <p><a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a> reported histological changes, showing no benefit of topical bleomycin when compared with placebo: RR 0.49, 95% CI 0.22 to 1.10 (<a href="./references#CD001829-fig-0019" title="">Analysis 5.3</a>). </p> </section> <section id="CD001829-sec-0106"> <h5 class="title">Safety</h5> <p>Topical bleomycin caused adverse effects of varying severity in 100% of participants (see <a href="#CD001829-tbl-0008">Table 2</a>). Participants in the bleomycin group developed erythema with erosion. Erythema developed in the placebo group; 60% of the bleomycin group reported discomfort but did not require analgesics. The trial found no evidence of systemic toxicity. </p> </section> </section> <section id="CD001829-sec-0107"> <h4 class="title">Bowman‐Birk Inhibitor versus placebo</h4> <p>A single study tested the Bowman‐Birk inhibitor against placebo (<a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a>). </p> <section id="CD001829-sec-0108"> <h5 class="title">Oral cancer development</h5> <p>Cancer development was not among the outcomes of the study testing the Bowman‐Birk inhibitor. </p> </section> <section id="CD001829-sec-0109"> <h5 class="title">Clinical resolution</h5> <p>The topical Bowman‐Birk inhibitor showed no benefit for clinical resolution when compared with placebo: RR 1.00, 95% CI 0.91 to 1.09 (<a href="./references#CD001829-fig-0020" title="">Analysis 6.1</a>). </p> </section> <section id="CD001829-sec-0110"> <h5 class="title">Improvement of histological features</h5> <p>Data on histological changes from <a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a> were not available for analysis, but study authors reported no statistically significant differences in histological changes between study arms. </p> </section> <section id="CD001829-sec-0111"> <h5 class="title">Safety</h5> <p>The Bowman‐Birk inhibitor caused adverse effects of varying severity in 49% of participants (see <a href="#CD001829-tbl-0008">Table 2</a>). </p> </section> </section> <section id="CD001829-sec-0112"> <h4 class="title">Sensitivity analysis</h4> <p>We did not undertake sensitivity analysis excluding studies at high or unclear risk of bias, as the only study at low risk of bias was not included in a meta‐analysis (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001829-sec-0113" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001829-sec-0113"></div> <p>Leukoplakia is the most common potentially malignant oral disorder. Although rates of oral ccancer development may vary among studies, probably as the result of differences in diagnostic criteria for leukoplakia and follow‐up intervals, the morbidity and mortality associated with oral cancer suggest that leukoplakia is a relevant health issue for affected individuals. Yet, of the 14 studies included in the present review, none evaluated a surgical intervention nor the effect of habit cessation, and only three studies provided data on the effects of a medical or complementary treatment on cancer incidence. </p> <section id="CD001829-sec-0114"> <h3 class="title" id="CD001829-sec-0114">Summary of main results</h3> <p>At present, there is no evidence that any of the medical or complementary treatments studied for people with leukoplakia can reduce the likelihood of oral cancer development. It should be noted that this conclusion is based on only three studies, namely, those testing systemic vitamin A, systemic beta carotene and topical bleomycin. These studies, which were at high or unclear risk of bias, included relatively few participants and had limited follow‐up. Overall, the quality of the evidence was very low. </p> <p>Clinical change, in terms of variation in lesion size, was an outcome reported by all studies, although esearchers used different methods of measurement. Some single studies suggested effectiveness of some proposed treatments, namely, vitamin A, beta carotene and lycopene, in achieving complete clinical resolution of lesions more often than placebo (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>). Similarly, single studies showed that vitamin A and lycopene provided some benefit in terms of improvement in histological features (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>; <a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a>). </p> <p>Leukoplakias generally are not associated with significant signs and symptoms, and the risk of developing cancer is relatively low (i.e. many patients with leukoplakia receive treatment that is not necessary). Therefore, proposed treatments should have minimal propensity for adverse effects. The proportion of participants reporting adverse effects varied between 0 and 100% in the active arms of the included trials, and between 0 and 90% in the placebo arms; however adverse effects were always more common in the study group than in the control group (see <a href="#CD001829-tbl-0008">Table 2</a>). It seems likely that interventions were well accepted by participants because drop‐out rates were similar between treatment and control groups (see <a href="#CD001829-tbl-0009">Table 3</a>); however, follow‐up may not have been long enough to permit this assessment. Adverse effects caused participants to withdraw in three studies: when systemic 13‐cis‐retinoic acid induced severe conjunctivitis and hypertriglyceridaemia (<a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a>); when intolerable mouth pain followed the initial ketorolac mouthrinse (<a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a>); and in two participants treated with celecoxib, because of vision abnormality and hypertension in one, and ischaemic cerebrovascular accident in another (<a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a>). </p> <div class="table" id="CD001829-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Participants leaving the studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Active treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bowman Birk inhibitor concentrate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical bleomycin vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic 13‐cis‐retinoic acid (from 1 to 2 mg/kg per day) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic and topical tea vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Freeze‐dried black raspberry gel vs placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketorolac oral rinse vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta carotene and vitamin C vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Celecoxib vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical 13‐cis‐retinoic acid vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin A (300,000 IU per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta carotene (360 mg per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lycopene (8 mg or 4 mg) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin A (200,000 IU per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese herbal mixture vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/60</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>vs = versus</p> </div> </div> </section> <section id="CD001829-sec-0115"> <h3 class="title" id="CD001829-sec-0115">Overall completeness and applicability of evidence</h3> <p>Less than half (33% to 42%) of people with leukoplakia who develop oral cancer do so within two years of diagnosis (<a href="./references#CD001829-bbs2-0055" title="LindPO . Malignant transformation in oral leukoplakia. Scandinavian Journal of Dental Research1987;95(6):449‐55. ">Lind 1987</a>; <a href="./references#CD001829-bbs2-0068" title="SilvermanSJr , GorskyM , LozadaF . Oral leukoplakia and malignant transformation. A follow‐up study of 257 patients. Cancer1984;53(3):563‐8. ">Silverman 1984</a>), and the incidence of oral cancer increases with the duration of follow‐up (<a href="./references#CD001829-bbs2-0067" title="ShiuMN , ChenTH , ChangSH , HahnLJ . Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan. British Journal of Cancer2000;82(11):1871‐4. ">Shiu 2000</a>). Therefore, to properly test the effects of treatments on cancer incidence, it would be necessary to plan studies with large groups of participants and a long follow‐up period ‐ ideally, multi‐centre randomised controlled trials (RCTs) assessing outcomes at 10 years. As the duration of the studies included in this review was less than 12 months in all but four studies (<a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a>; <a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a>; <a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a>), cancer incidence rates are likely to be underestimated. Indeed, most of the studies did not include cancer incidence as an endpoint, but rather employed outcomes that assessed clinical or histological markers or both. Although easier to perform, studies using such outcomes pose a double problem: first, there is little evidence of the predictive value of many of those outcomes; second, they are difficult to compare. In addition, widespread outcomes, such as dysplasia grade, may be affected by high inter‐observer and even intra‐observer variation (<a href="./references#CD001829-bbs2-0039" title="AbbeyLM , KaugarsGE , GunsolleyJC , BurnsJC , PageDG , SvirskyJA , et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics1995;80(2):188‐91. ">Abbey 1995</a>; <a href="./references#CD001829-bbs2-0053" title="KarabulutA , ReibelJ , TherkildsenMH , PraetoriusF , NielesenHW , DabelsteenE . Observer variability in the histologic assessment of oral premalignant lesions. Journal of Oral Pathology Medicine1995;24(5):198‐200. ">Karabulut 1995</a>). </p> <p>It is noteworthy that, although surgery is the first choice in leukoplakia management for many clinicians, there is an absence of RCTs comparing the effects of surgical excision versus no treatment or placebo (<a href="./references#CD001829-bbs2-0058" title="MarleyJJ , CowanCG , LameyPJ , LindenGJ , JohnsonNW , WarnakulasuriyaKA . Management of potentially malignant oral mucosal lesions by consultant UK oral and maxillofacial surgeons. British Journal of Oral and Maxillofacial Surgery1998;34(1):28‐36. ">Marley 1998</a>). The only data available are from observational studies comparing rates of cancer incidence in people who did or did not undergo surgical treatment for oral leukoplakias. Such studies have differences in diagnostic and inclusion criteria, follow‐up interval, participant characteristics and surgical techniques employed (scalpel, laser, cryotherapy). They show highly variable results and sometimes are conflicting in their conclusions (<a href="./references#CD001829-bbs2-0063" title="SaitoT , SugiuraC , HiraiA , NotaniK , TotsukaY , ShindohM , et al. Development of squamous cell carcinoma from pre‐existent oral leukoplakia: with respect to treatment modality. International Journal of Oral and Maxillofacial Surgery2001;30(1):49‐53. ">Saito 2001</a>; <a href="./references#CD001829-bbs2-0065" title="SchepmanKP , van derMeijEH , SmeeleLE , van derWaalI . Malignant transformation of oral leukoplakia: a follow‐up study of a hospital‐based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncology1998;34(4):270‐5. ">Schepman 1998</a>). In addition, on the basis of animal and clinical studies, it has been speculated that surgery itself might act to promote carcinogenesis in pre‐malignant oral lesions (<a href="./references#CD001829-bbs2-0051" title="HolmstrupP . Can we prevent malignancy by treating premalignant lesions?. Oral Oncology2009;45:549‐50. ">Holmstrup 2009</a>). Trials evaluating interventions directed against risk factors (e.g. smoking) are also missing. </p> <p>The applicability of results of two of the included studies (<a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a>; <a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a>) should be considered in the context of their different risk factor profile as the participants were all betel quid chewers, a risk factor uncommon in individuals from geographical areas outside South Asia. </p> <p>Leukoplakias with different histological or molecular characteristics may have different risks of transforming into cancer. However, the value of predictive factors proposed so far in the literature requires sound confirmatory data. The presence of epithelial dysplasia may be predictive of a transformation to oral cancer and the risk of cancer may increase with the severity of dysplastic changes (<a href="./references#CD001829-bbs2-0057" title="LumermanH , FreedmanP , KerpelS . Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics1995;79(3):321‐9. ">Lumerman 1995</a>; <a href="./references#CD001829-bbs2-0065" title="SchepmanKP , van derMeijEH , SmeeleLE , van derWaalI . Malignant transformation of oral leukoplakia: a follow‐up study of a hospital‐based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncology1998;34(4):270‐5. ">Schepman 1998</a>; <a href="./references#CD001829-bbs2-0075" title="WarnakulasuriyaS , KovacevicT , MaddenP , CouplandVH , SperandioM , OdellE , et al. Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10‐year period in South East England. Journal of Oral Pathology &amp; Medicine2011;40:677‐83. ">Warnakulasuriya 2011</a>), although this hypothesis has been recently challenged (<a href="./references#CD001829-bbs2-0050" title="HolmstrupP , VedtofteP , ReibelJ , StoltzeK . Long‐term treatment outcome of oral premalignant lesions. Oral Oncology2006;42(5):461‐74. ">Holmstrup 2006</a>). Unfortunately, the available data did not allow us to perform a subgroup analysis of lesions with and without dysplasia, thus it is not possible to establish whether any particular treatment may be more indicated in the presence of dysplasia of different severity. Many different molecular biomarkers have been proposed, but no single marker or battery of markers seems predictive enough to be implemented during clinical care. </p> </section> <section id="CD001829-sec-0116"> <h3 class="title" id="CD001829-sec-0116">Quality of the evidence</h3> <p>Of the studies included in the present review, we judged one as having low risk of bias, six asunclear risk of bias and seven ashigh risk of bias. Although these studies were randomised trials, information about randomisation methods was missing or incomplete in most studies. In particular, methods used for random sequence generation were unclear in eight out of 15 studies, and details on allocation concealment were missing in 10 out of 15 studies. The body of evidence for cancer incidence comprises three studies investigating three different treatments: vitamin A, beta carotene and topical bleomycin. We assessed these studies as having very low quality according to GRADE (Grades of Recommendation, Assessment, Development and Evaluation) assessment criteria (see <a href="./full#CD001829-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD001829-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001829-tbl-0005">summary of findings Table 5</a>). Thus, the quality and the number of included trials, often with short follow‐up times, suggest cautious interpretation of results. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001829-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD001829-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD001829-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD001829-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.1 Cancer development" data-id="CD001829-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.1 Cancer development </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.2 Oral lesion not completely resolved" data-id="CD001829-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Vitamin A or retinoids vs placebo, outcome: 1.2 Oral lesion not completely resolved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.1 Cancer development" data-id="CD001829-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.1 Cancer development </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.2 Oral lesion not completely resolved" data-id="CD001829-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Beta carotene or carotenoids vs placebo, outcome: 2.2 Oral lesion not completely resolved </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin A or retinoids versus placebo, Outcome 1 Oral cancer development." data-id="CD001829-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Vitamin A or retinoids versus placebo, Outcome 1 Oral cancer development.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin A or retinoids versus placebo, Outcome 2 Clinical resolution." data-id="CD001829-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Vitamin A or retinoids versus placebo, Outcome 2 Clinical resolution.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Vitamin A or retinoids versus placebo, Outcome 3 Improvement of histological features." data-id="CD001829-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Vitamin A or retinoids versus placebo, Outcome 3 Improvement of histological features. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 1 Oral cancer development." data-id="CD001829-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 1 Oral cancer development.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 2 Clinical resolution." data-id="CD001829-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 2 Clinical resolution.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 3 Improvement of histological features." data-id="CD001829-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Beta carotene or carotenoids versus placebo, Outcome 3 Improvement of histological features. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 NSAIDs versus placebo, Outcome 1 Clinical resolution." data-id="CD001829-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 NSAIDs versus placebo, Outcome 1 Clinical resolution.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Herbal extracts versus placebo, Outcome 1 Clinical resolution." data-id="CD001829-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Herbal extracts versus placebo, Outcome 1 Clinical resolution.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Herbal extracts versus placebo, Outcome 2 Improvement of histological features." data-id="CD001829-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Herbal extracts versus placebo, Outcome 2 Improvement of histological features. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Topical bleomycin versus placebo, Outcome 1 Oral cancer development." data-id="CD001829-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Topical bleomycin versus placebo, Outcome 1 Oral cancer development.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Topical bleomycin versus placebo, Outcome 2 Clinical resolution." data-id="CD001829-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Topical bleomycin versus placebo, Outcome 2 Clinical resolution.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Topical bleomycin versus placebo, Outcome 3 Improvement of histological features." data-id="CD001829-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Topical bleomycin versus placebo, Outcome 3 Improvement of histological features. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001829-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/urn:x-wiley:14651858:media:CD001829:CD001829-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_t/tCD001829-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Bowman‐Birk inhibitor versus placebo, Outcome 1 Clinical resolution." data-id="CD001829-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Bowman‐Birk inhibitor versus placebo, Outcome 1 Clinical resolution.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/media/CDSR/CD001829/image_n/nCD001829-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001829-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vitamin A or retinoids versus placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Systemic or topical vitamin A vs placebo for treating leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with oral leukoplakia<br/> <b>Intervention:</b> vitamin A or retinoids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with vitamin A or retinoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer development at 24 months from start of treatment (treatment lasted 12 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>93 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 1000<br/> (1 to 191) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.11<br/> (0.01 to 2.05) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study evaluated systemic treatment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical resolution (not completely resolved) at 4 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Studies could not be combined in meta‐analysis</p> <p>One study evaluated topical treatment and did not find evidence of benefit</p> <p>3 studies of systemic vitamin A ‐ 2 showed benefit in terms of clinical resolution, and 1 did not </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved) at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>889 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>382 per 1000 (213 to 676)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.43 (0.24 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study evaluated systemic treatment</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention at 4 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>3 studies (1 each evaluating topical acitretin, topical 13‐cis‐retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13‐cis‐retinoic acid (1 to 2 mg/kg/d) caused adverse effects of varying severity in 79% of participants </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus; d = day </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>From event rate in control group<br/> <sup>a</sup>Downgraded 3 levels as single small study at unclear risk of bias with very imprecise result<br/> <sup>b</sup>Downgraded as single small study </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Vitamin A or retinoids versus placebo for treating oral leukoplakia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001829-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with oral leukoplakia<br/> <b>Intervention:</b> systemic beta carotene<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with beta carotene or carotenoids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer development at</p> <p>24 months from start of treatment (treatment lasted 12 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>108 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000<br/> (26 to 238) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.73<br/> (0.24 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical resolution (not completely resolved) at</p> <p>5 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>The 3 studies could not be combined in meta‐analysis. 2 found benefit for systemic beta carotene, and 1 did not </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved)</p> <p>at 5 months (treatment lasted 3 months)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>833 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1000</p> <p>(100 to 383)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.24 (0.12 to 0.46)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention at 5 to 12 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Systemic beta carotene did not cause any adverse effects in 1 study supplementing 10 mg/d, and caused adverse effects of varying severity in 9% of participants in another study supplementing 360 mg/wk </p> <p>No adverse effects were reported by participants treated with systemic lycopene in one study </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus; d = day; wk = week </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> From event rate in control group<br/> <sup>a</sup>Downgraded 3 levels for unclear or high risk of bias and serious imprecision<br/> <sup>b</sup>Downgraded 2 levels as single small study at unclear risk of bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Systemic beta carotene or carotenoids vs placebo for treating oral leukoplakia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001829-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Non‐steroidal anti‐inflammatory drugs (NSAIDs) vs placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>NSAIDs vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral leukoplakia </p> <p><b>Intervention:</b> NSAIDs </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with NSAIDs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer development</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical resolution (not completely resolved) at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>1 study evaluated systemic treatment and 1 evaluated topical treatment. Neither found benefit for NSAIDs </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved)</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safety of the intervention</p> <p>over 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Systemic celecoxib (1 study) ‐ 32 intervention participants reported 56 adverse effects and 20 placebo participants in the placebo group reported 20 adverse effects. Minor adverse events included dizziness, diarrheoa and abdominal pain. 4 participants (2 from the placebo group and 2 from an intervention group) had grade 3 adverse events. 2 participants permanently discontinued treatment owing to an adverse event (grade 2 vision abnormality and hypertension in a participant receiving 400 mg twice daily of celecoxib and a grade 3 ischaemic cerebrovascular accident in a participant receiving 200 mg twice daily of celecoxib) </p> <p>Ketorolac oral rinse (1 study) caused adverse effects of varying severity in 29% of participants </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Non‐steroidal anti‐inflammatory drugs (NSAIDs) vs placebo for treating oral leukoplakia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001829-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Herbal extracts vs placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Herbal extracts vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral leukoplakia </p> <p><b>Intervention:</b> herbal extracts ‐ tea components; a Chinese herbal mixture; curcumin chewing gum; freeze‐dried black raspberry gel </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with herbal extracts</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer development</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical resolution (not completely resolved) at 3 to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>3 studies (1 of freeze‐dried black raspberry gel, 1 of green tea extract capsules and 1 of mixed tea treatment) did not find evidence of benefit for the intervention </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved) at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>2 studies (1 of green tea extract capsules and 1 of freeze‐dried raspberry gel) did not find evidence of benefit from these interventions </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention up to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>3 studies measured adverse effects: green tea extract capsules caused high frequency (93%) of adverse effects of varying severity in 1 study; the mixed tea treatment study did not mention adverse effects; freeze‐dried black raspberry gel did not cause any adverse effects </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Herbal extracts vs placebo for treating oral leukoplakia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001829-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Topical bleomycin vs placebo for treating oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Topical bleomycin vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with oral leukoplakia<br/> <b>Intervention:</b> topical bleomycin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with topical bleomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cancer development up to 7 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>250 per 1000</p> <p>(27 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 3.00<br/> (0.32 to 27.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical resolution (not completely resolved)</p> <p>at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>917 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>504 per 1000 (266 to 954)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.55 (0.29 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved) at 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>818 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>401 per 1000 (180 to 900)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.49 (0.22 to 1.10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention up to 3 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>"All patients in the bleomycin group developed erythema with erosion by the end of the applications, whereas erythema developed in the placebo group. Discomfort was reported by 60% of the bleomycin group, but analgesics were not required. Taste of the topical application as well‐tolerated. There was no observed systemic toxicity in the patient groups" </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but may be substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> From event rate in control group<br/> <sup>a</sup>Downgraded 3 levels as a single small study at unclear risk of bias with imprecise result </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Topical bleomycin vs placebo for treating oral leukoplakia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001829-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bowman‐Birk inhibitor versus placebo for oral leukoplakia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Bowman‐Birk inhibitor vs placebo for treating oral leukoplakia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with oral leukoplakia </p> <p><b>Intervention:</b> Bowman‐Birk inhibitor </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with Bowman‐Birk inhibitor</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cancer development</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical resolution (not completely resolved) at 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>957 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>957 per 1000</p> <p>(871 to 1000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (0.91 to 1.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological changes (not improved) at 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Safety of the intervention up to 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Trial authors reported that there were no significant adverse effects. 33 participants in the intervention group reported 75 adverse effects. 25 participants in the placebo group reported 63 adverse effects </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI)<br/> CI = confidence interval; RR = risk ratio; vs = versus </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate<br/> <b>Very low quality:</b> We are very uncertain about the estimate </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> From event rate in control group<br/> <sup>a</sup>Downgraded 2 levels as a single small study at high risk of bias </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Bowman‐Birk inhibitor versus placebo for oral leukoplakia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001829-tbl-0007"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participants with dysplastic leukoplakia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants with dysplastic leukoplakia (any grade)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.75%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73.2%</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Participants with dysplastic leukoplakia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001829-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants reporting adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Active treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bowman Birk inhibitor concentrate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75 reported from 33 of 67 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63 reported from 25 of 65 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minor adverse effects</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical bleomycin vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bleomycin group ‐ erythema and erosion (100%), discomfort (60%)</p> <p>Placebo group ‐ erythema only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic 13‐cis‐retinoic acid (from 1 to 2 mg/kg per day) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cheilitis, facial erythema, dryness and peeling of skin, conjunctivitis, hypertriglyceridaemia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic and topical tea vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured or reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Freeze‐dried black raspberry gel vs placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No participant experienced any treatment‐associated complications"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketorolac oral rinse vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pain, toxicity grade 1 and 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta carotene and vitamin C vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No untoward side effects were noted</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Celecoxib vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56 reported from 32 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 reported from 18 participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 participants presented grade 3 adverse events: 2 in placebo arm and 2 in active treatment arm. 2 participants from intervention groups discontinued treatment owing to adverse effects (1 grade 2 and 1 grade 3). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical 13‐cis‐retinoic acid vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No side effects from the use of the gel<br/> were ever observed" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin A (300,000 IU per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache, muscular pain, dry mouth</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta carotene (360 mg per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache, muscular pain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lycopene (8 mg or 4 mg) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No side effects, toxicity of any sort were encountered in the complete duration of the therapy" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin A (200,000 IU per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"The administered doses of vitamin A did not produce any detectable adverse<br/> effects during the trial period" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese herbal mixture vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not measured or reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0014" title="TsaoAS , LiuD , MartinJ , TangXM , LeeJJ , El‐NaggarAK , et al. Phase II randomized, placebo‐controlled trial of green tea extract in patients with high‐risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.)2009;2:931‐41. ">Tsao 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green tea extract at different doses (500, 750 or 1000 mg/m<sup>2</sup> daily) vs placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grade 1 to 2 adverse events including insomnia, headache, nausea and nervousness</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>vs = versus</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Participants reporting adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001829-tbl-0009"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Participants leaving the studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Active treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0001" title="ArmstrongWB , TaylorTH , KennedyAR , MelroseRJ , MessadiDV , GuM , et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prevention Research (Philadelphia, Pa.)2013;6:410‐8. ">Armstrong 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bowman Birk inhibitor concentrate vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0002" title="EpsteinJB , WongFL , MillnerA , LeND . Topical bleomycin treatment of oral leukoplakia: a randomized double‐blind clinical trial. Head &amp; Neck1994;16(6):539‐44. ">Epstein 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical bleomycin vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0003" title="HongWK , EndicottJ , ItriLM , DoosW , BatsakisJG , BellR , et al. 13‐cis‐retinoic acid in the treatment of oral leukoplakia. New England Journal of Medicine1986;315(24):1501‐5. ">Hong 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic 13‐cis‐retinoic acid (from 1 to 2 mg/kg per day) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0004" title="LiN , SunZ , HanC , ChenJ . The chemopreventive effects of tea on human oral precancerous mucosa lesions. Proceedings of the Society for Experimental Biology and Medicine1999;220(4):218‐24. ">Li 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Systemic and topical tea vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0005" title="MallerySR , TongM , ShumwayBS , CurranAE , LarsenPE , NessGM , et al. Topical application of a mucoadhesive freeze‐dried black raspberry gel induces clinical and histologic regression and reduces loss of heterozygosity events in premalignant oral intraepithelial lesions: results from a multicentered, placebo‐controlled clinical trial. Clinical Cancer Research2014;20(7):1910‐24. ">Mallery 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Freeze‐dried black raspberry gel vs placebo gel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0006" title="MulshineJL , AtkinsonJC , GreerRO , PapadimitrakopoulouVA , VanWaesC , RudyS , et al. Randomized, double‐blind, placebo‐controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clinical Cancer Research2004;10(5):1565‐73. ">Mulshine 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ketorolac oral rinse vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0007" title="NagaoT , WarnakulasuriyaS , FukanoH , NakamuraT , KatoS , YamamotoK , et al. A randomized controlled trial for the treatment of oral leukoplakia with the aid of chemopreventive agents. Journal of Oral and Maxillofacial Surgery2007;65(9 Suppl):41.e6. NagaoT , WarnakulasuriyaS , FukanoH , SuzukiK , ShimozatoK , HashimotoS . A randomised trial for preventing malignant transformation of oral leukoplakia. Oral Surgery2010;3:103–14. NagaoT , WarnakulasuriyaS , NakamuraT , KatoS , YamamotoK , FukanoH , et al. Treatment of oral leukoplakia with a low‐dose of beta‐carotene and vitamin C supplements: a randomized controlled trial. International Journal of Cancer2015;136:1708‐17. NagaoT , WarnakulasuriyaS , SakumaH , SuzukiK , HashimotoS . Is response to chemoprevention in oral leukoplakia determined by p53 expression?. Oral Diseases2010;16:518. ">Nagao 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta carotene and vitamin C vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0008" title="PapadimitrakopoulouVA , WilliamWNJr , DannenbergAJ , LippmanSM , LeeJJ , OndreyFG , et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clinical Cancer Research2008;14:2095‐101. ">Papadimitrakopoulou 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Celecoxib vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0009" title="PiattelliA , FioroniM , SantinelliA , RubiniC . bcl‐2 expression and apoptotic bodies in 13‐cis‐retinoic acid (isotretinoin)‐topically treated oral leukoplakia: a pilot study. Oral Oncology1999;35(3):314‐20. ">Piattelli 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topical 13‐cis‐retinoic acid vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin A (300,000 IU per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0010" title="SankaranarayananR , MathewB , VargheseC , SudhakaranPR , MenonV , JayadeepA , et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncology1997;33(4):231‐6. ">Sankaranarayan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Beta carotene (360 mg per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0011" title="SinghM , KrishanappaR , BagewadiA , KeluskarV . Efficacy of oral lycopene in the treatment of oral leukoplakia. Oral Oncology2004;40(6):591‐6. ">Singh 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lycopene (8 mg or 4 mg) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0012" title="StichHF , HornbyAP , MathewB , SankaranarayananR , NairMK . Response of oral leukoplakias to the administration of vitamin A. Cancer Letters1988;40(1):93‐101. ">Stich 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin A (200,000 IU per week) vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/35</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD001829-bbs2-0013" title="SunZ , GuanX , LiN , LiuX , ChenX . Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncology2010;46:105‐10. ">Sun 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese herbal mixture vs placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/60</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>vs = versus</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Participants leaving the studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/full#CD001829-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001829-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin A or retinoids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Oral cancer development <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Topical treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement of histological features <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vitamin A or retinoids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001829-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Beta carotene or carotenoids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Oral cancer development <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.24, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement of histological features <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Beta carotene or carotenoids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001829-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NSAIDs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.83, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Topical treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.81, 1.10]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NSAIDs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001829-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Herbal extracts versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Topical treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Systemic plus topical treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Improvement of histological features <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Systemic treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Topical treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Herbal extracts versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001829-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Topical bleomycin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Oral cancer development <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Improvement of histological features <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Topical bleomycin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001829-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bowman‐Birk inhibitor versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical resolution <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Bowman‐Birk inhibitor versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001829.pub4/references#CD001829-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001829.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD001829-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD001829-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001829-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD001829-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD001829-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD001829-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001829-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD001829-note-0018">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001829-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001829\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001829\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001829\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001829\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001829\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=l7AWCCEw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001829.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001829.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001829.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001829.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001829.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726279359"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001829.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726279363"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001829.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e8fc6e90ff431',t:'MTc0MDcyNjI3OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 